Nanoliposome Peptide Vaccine Shrinks HER2-Positive Breast Tumors in Mice

What the researchers found

The Lip-DOPE-MPL-GP2 formulation generated the highest IFN-γ+ CD8+ T cell and cytotoxic T lymphocyte responses among all tested formulations, as measured by ELISpot and flow cytometry. In both prophylactic (vaccination before tumor challenge) and therapeutic (vaccination after tumor establishment) experiments, mice immunized with this formulation had smaller tumors and longer survival compared to other groups. The combination of DOPE (fusogenic lipid) and MPL (adjuvant) was key to both the immune response and anti-tumor efficacy.

Why it matters

GP2 is a HER2-derived peptide already in human clinical trials as a breast cancer vaccine. This study shows that delivering it via nanoliposomes dramatically enhances the immune response compared to standard vaccine formulations. If this improved delivery translates to humans, it could make peptide-based cancer vaccines far more effective for the approximately 15-20% of breast cancers that overexpress HER2.

How the study worked

GP2 peptide was conjugated to maleimide-mPEG2000-DSPE micelles and post-inserted into liposomes containing DMPC, DMPG, DOPE, and MPL. BALB/c mice were immunized with various formulations. Immune responses were evaluated by ELISpot and intracellular cytokine flow cytometry. Anti-tumor efficacy was tested in both prophylactic and therapeutic TUBO xenograft models measuring tumor size and survival.

What this study cannot tell us

This is a mouse study using a xenograft model, which may not accurately predict human immune responses or therapeutic outcomes. The TUBO model is a specific mouse breast cancer system that may differ from human HER2-positive tumors. Specific tumor size reductions and survival data are not quantified in the abstract. Long-term efficacy and safety in larger animal models or humans have not been assessed.

How to read the evidence

This is a preclinical mouse study demonstrating proof of concept for an improved peptide vaccine delivery system. While the results are promising and well-controlled, translation to human breast cancer requires clinical trials.

When this study was published

Published in 2017, this study contributed to the development of nanoliposome-based cancer vaccine platforms that have continued to advance toward clinical testing.

The bigger picture

Peptide-based cancer vaccines have struggled with weak immune responses when delivered using traditional methods. Nanoliposome delivery that combines targeted antigen presentation (GP2 peptide), enhanced cell entry (fusogenic DOPE lipid), and immune activation (MPL adjuvant) represents a sophisticated platform approach that could be applied beyond breast cancer to any peptide vaccine target.

Questions still open

• Does this nanoliposome delivery platform improve GP2 vaccine efficacy in human clinical trials?
• Could this formulation approach be applied to other cancer peptide vaccines beyond HER2-derived antigens?
• How does the Lip-DOPE-MPL-GP2 vaccine compare to current HER2-targeted therapies like trastuzumab in combination settings?

Common questions

Read the original research

Conjugated nanoliposome with the HER2/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model.

PloS one, 12(10), e0185099

Citation

Razazan, Atefeh; Behravan, Javad; Arab, Atefeh; Barati, Nastaran; Arabi, Leila; Gholizadeh, Zahra; Hatamipour, Mahdi; Reza Nikpoor, Amin; Momtazi-Borojeni, Amir Abbas; Mosaffa, Fatemeh; Ghahremani, Mohamad Hosein; Jaafari, Mahmoud Reza. (2017). Conjugated nanoliposome with the HER2/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model.. PloS one, 12(10), e0185099. https://doi.org/10.1371/journal.pone.0185099